[go: up one dir, main page]

CY1125797T1 - Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου - Google Patents

Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου

Info

Publication number
CY1125797T1
CY1125797T1 CY20211100466T CY211100466T CY1125797T1 CY 1125797 T1 CY1125797 T1 CY 1125797T1 CY 20211100466 T CY20211100466 T CY 20211100466T CY 211100466 T CY211100466 T CY 211100466T CY 1125797 T1 CY1125797 T1 CY 1125797T1
Authority
CY
Cyprus
Prior art keywords
nucleic acid
acid sequence
domain
ligand
cancer
Prior art date
Application number
CY20211100466T
Other languages
English (en)
Inventor
Alfredo PERALES-PUCHALT
Jose R. Conejo-Garcia
Original Assignee
The Wistar Institute Of Anatomy And Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute Of Anatomy And Biology filed Critical The Wistar Institute Of Anatomy And Biology
Publication of CY1125797T1 publication Critical patent/CY1125797T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Παρέχεται αλληλουχία νουκλεϊκού οξέος, η οποία κωδικοποιεί μια χιμαιρική πρωτεΐνη η οποία εμπεριέχει έναν προσδέτη ο οποίος εμπεριέχει μια αλληλουχία φυσικώς προκύπτουσας ή τροποποιημένης ωοθυλακιοτρόπου ορμόνης, π.χ., μια αλληλουχία FSHp, ή κάποιο θραύσμα αυτής, όπου ο εν λόγω προσδέτης δεσμεύεται στον υποδοχέα της ανθρώπινης θυλακιοτρόπου ορμόνης (FSH)+, συνδεδεμένο είτε σε (α) μια αλληλουχία νουκλεϊκού οξέος που κωδικοποιεί μια εξωκυττάρια επικράτεια γιγγλύμου, μια διαμεμβρανική επικράτεια, μια συνδιεγερτική περιοχή σηματοδότησης και μια ενδοεπικράτεια σηματοδότησης· είτε σε (β) μια αλληλουχία νουκλεϊκού οξέος η οποία κωδικοποιεί έναν προσδέτη που δεσμεύεται σε NKG2D. Παρέχονται, επίσης, ο διαβιβαστής ο οποίος περιέχει την αλληλουχία νουκλεϊκού οξέος, οι ούτως κωδικοποιημένες χιμαιρικές πρωτεΐνες και τα τροποποιημένα κύτταρα Τ που εκφράζουν τη χιμαιρική πρωτεΐνη, καθώς και οι μέθοδοι χρήσης των συγκεκριμένων συνθέσεων για τη θεραπευτική αντιμετώπιση των τύπων καρκίνου που εκφράζουν τον FSHR ή των ογκοκυττάρων.
CY20211100466T 2014-10-02 2021-05-31 Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου CY1125797T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059068P 2014-10-02 2014-10-02
US201562202824P 2015-08-08 2015-08-08
PCT/US2015/053128 WO2016054153A1 (en) 2014-10-02 2015-09-30 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CY1125797T1 true CY1125797T1 (el) 2024-02-16

Family

ID=55631412

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100466T CY1125797T1 (el) 2014-10-02 2021-05-31 Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου

Country Status (16)

Country Link
US (3) US10259855B2 (el)
EP (1) EP3200815B1 (el)
CN (2) CN114150018A (el)
CA (1) CA2989807C (el)
CY (1) CY1125797T1 (el)
DK (1) DK3200815T3 (el)
ES (1) ES2870607T3 (el)
HR (1) HRP20210705T1 (el)
HU (1) HUE054673T2 (el)
LT (1) LT3200815T (el)
PL (1) PL3200815T3 (el)
PT (1) PT3200815T (el)
RS (1) RS61929B1 (el)
SI (1) SI3200815T1 (el)
SM (1) SMT202100273T1 (el)
WO (1) WO2016054153A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073456A1 (en) * 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor
RU2018138122A (ru) * 2016-04-05 2020-05-12 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новая терапия
IT201600101852A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia dei tumori
IT201600101870A1 (it) * 2016-10-11 2018-04-11 Abresearch Srl Ligandi del recettore dell’ormone FSH nella diagnosi e nella terapia del neuroblastoma
KR102636093B1 (ko) * 2016-10-11 2024-02-13 온코그린 테라퓨틱스 에스아 종양의 진단 및 치료에서 fsh 호르몬 수용체의 리간드
EP3675878A4 (en) * 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
JP2021509903A (ja) * 2018-01-05 2021-04-08 マックスサイト インコーポレーティッド 癌の長期ｃａｒ処置
CN113613725A (zh) * 2018-11-05 2021-11-05 路德维格癌症研究所有限公司 人源化和变体TGF-β1特异性抗体及其方法和用途
WO2020146233A1 (en) * 2019-01-07 2020-07-16 H. Lee Moffitt Cancer Center And Research Institute Inc. Foxp1-ablated chimeric cells
CN113474458A (zh) * 2019-01-30 2021-10-01 威斯塔解剖学和生物学研究所 靶向癌症抗原的dna编码的双特异性t细胞连接子以及在癌症治疗中的使用方法
EP3952887A4 (en) * 2019-04-12 2023-05-03 Emory University COMPOSITIONS AND METHODS FOR PROMOTING THE CYTOTOXICITY OF HEMATOPOIETIC CELLS
WO2021168421A1 (en) * 2020-02-20 2021-08-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of enhancing immunotherapy using er stress pathway inhibitors
US20240101626A1 (en) * 2021-02-12 2024-03-28 Kar Muthumani Consensus prostate antigens, nucleic acid molecules encoding the same, and vaccines and uses comprising the same
CN115975056B (zh) * 2023-02-07 2023-12-01 徐州医科大学 利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702702A (en) 1992-03-30 1997-12-30 The Wistar Institute Of Anatomy And Biology Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
IL161584A0 (en) 2001-11-21 2004-09-27 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2004022706A2 (en) 2002-09-04 2004-03-18 The Trustees Of The University Of Pennsylvania Immune cell receptor ligand and immune cell receptor
EP2000160A3 (en) 2002-10-30 2009-03-11 Gambro Lundia AB Method and apparatuses for determining the efficiency of dialysis
HUE033576T2 (en) 2004-01-23 2017-12-28 Msd Italia Srl Chimpanzee adenovirus vaccine carriers
US7803611B2 (en) 2005-02-03 2010-09-28 Benitec, Inc. RNAi expression constructs
GB0725201D0 (en) 2007-12-24 2008-01-30 Asterion Ltd Peptide fusion proteins
JP5616233B2 (ja) 2008-01-24 2014-10-29 エスペランス ファーマシューティカルズＥｓｐｅｒａｎｃｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ 溶解ドメイン融合コンストラクト及びその生成及び使用方法
EP2090322A1 (en) 2008-02-18 2009-08-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fsh receptor ligands for diagnosis and therapy of cancer
ES2733067T3 (es) * 2008-12-19 2019-11-27 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
WO2013063019A1 (en) 2011-10-28 2013-05-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor t cells
WO2014078533A1 (en) * 2012-11-15 2014-05-22 Esperance Pharmaceuticals, Inc. Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
CN103509121B (zh) * 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
WO2016073456A1 (en) 2014-11-04 2016-05-12 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor or chimeric antigen receptor

Also Published As

Publication number Publication date
DK3200815T3 (da) 2021-05-10
US20190248862A1 (en) 2019-08-15
LT3200815T (lt) 2021-07-26
US20170226176A1 (en) 2017-08-10
CN106999552A (zh) 2017-08-01
SI3200815T1 (sl) 2021-11-30
WO2016054153A1 (en) 2016-04-07
CA2989807C (en) 2023-07-04
HRP20210705T1 (hr) 2021-07-23
PL3200815T3 (pl) 2021-10-18
CA2989807A1 (en) 2016-04-07
CN106999552B (zh) 2021-12-28
EP3200815B1 (en) 2021-03-03
SMT202100273T1 (it) 2021-07-12
EP3200815A1 (en) 2017-08-09
ES2870607T3 (es) 2021-10-27
RS61929B1 (sr) 2021-06-30
HUE054673T2 (hu) 2021-09-28
US10259855B2 (en) 2019-04-16
US11248033B2 (en) 2022-02-15
EP3200815A4 (en) 2018-04-25
CN114150018A (zh) 2022-03-08
PT3200815T (pt) 2021-05-07
US20220185861A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
CY1125797T1 (el) Μεθοδοι και συνθεσεις για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1126145T1 (el) Κατασκευασματα αντισωματων για flt3 και cd3
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CY1121934T1 (el) Αντισωματα anti-fcrn
EA202091710A1 (ru) Антитела против cd73 и способы их применения
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2023003463A (es) Receptores de linfocitos t e inmunoterapias basadas en el uso de los mismos contra canceres positivos para prame.
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
FI3240805T3 (fi) Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2021012074A (es) Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmunorreceptor (tigit).
EP4032544A3 (en) Novel t cell receptors and immune therapy using the same
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201890294A1 (ru) Химерный полипептидный комплекс и способы его получения и применения
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
PE20181066A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.